Literature DB >> 25848751

Mutational landscape and clonal architecture in grade II and III gliomas.

Hiromichi Suzuki1, Kosuke Aoki1, Kenichi Chiba2, Yusuke Sato3, Yusuke Shiozawa3, Yuichi Shiraishi2, Teppei Shimamura4, Atsushi Niida2, Kazuya Motomura5, Fumiharu Ohka6, Takashi Yamamoto5, Kuniaki Tanahashi5, Melissa Ranjit5, Toshihiko Wakabayashi5, Tetsuichi Yoshizato3, Keisuke Kataoka3, Kenichi Yoshida3, Yasunobu Nagata3, Aiko Sato-Otsubo3, Hiroko Tanaka2, Masashi Sanada3, Yutaka Kondo7, Hideo Nakamura8, Masahiro Mizoguchi9, Tatsuya Abe10, Yoshihiro Muragaki11, Reiko Watanabe12, Ichiro Ito12, Satoru Miyano2, Atsushi Natsume5, Seishi Ogawa3.   

Abstract

Grade II and III gliomas are generally slowly progressing brain cancers, many of which eventually transform into more aggressive tumors. Despite recent findings of frequent mutations in IDH1 and other genes, knowledge about their pathogenesis is still incomplete. Here, combining two large sets of high-throughput sequencing data, we delineate the entire picture of genetic alterations and affected pathways in these glioma types, with sensitive detection of driver genes. Grade II and III gliomas comprise three distinct subtypes characterized by discrete sets of mutations and distinct clinical behaviors. Mutations showed significant positive and negative correlations and a chronological hierarchy, as inferred from different allelic burdens among coexisting mutations, suggesting that there is functional interplay between the mutations that drive clonal selection. Extensive serial and multi-regional sampling analyses further supported this finding and also identified a high degree of temporal and spatial heterogeneity generated during tumor expansion and relapse, which is likely shaped by the complex but ordered processes of multiple clonal selection and evolutionary events.

Entities:  

Mesh:

Year:  2015        PMID: 25848751     DOI: 10.1038/ng.3273

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  307 in total

Review 1.  Neuro-oncology in 2015: Progress in glioma diagnosis, classification and treatment.

Authors:  Patrick Y Wen; David A Reardon
Journal:  Nat Rev Neurol       Date:  2016-01-18       Impact factor: 42.937

Review 2.  Statistical considerations on prognostic models for glioma.

Authors:  Annette M Molinaro; Margaret R Wrensch; Robert B Jenkins; Jeanette E Eckel-Passow
Journal:  Neuro Oncol       Date:  2015-12-08       Impact factor: 12.300

3.  Observation versus radiotherapy with or without temozolomide in postoperative WHO grade II high-risk low-grade glioma: a retrospective cohort study.

Authors:  Jingjing Wang; Lvjun Yan; Ping Ai; Yan He; Hui Guan; Zhigong Wei; Ling He; Xiaoli Mu; Yanhui Liu; Xingchen Peng
Journal:  Neurosurg Rev       Date:  2020-06-11       Impact factor: 3.042

Review 4.  Genetic and non-genetic clonal diversity in cancer evolution.

Authors:  James R M Black; Nicholas McGranahan
Journal:  Nat Rev Cancer       Date:  2021-03-16       Impact factor: 60.716

Review 5.  Genetic and molecular epidemiology of adult diffuse glioma.

Authors:  Annette M Molinaro; Jennie W Taylor; John K Wiencke; Margaret R Wrensch
Journal:  Nat Rev Neurol       Date:  2019-06-21       Impact factor: 42.937

Review 6.  Clonal expansion in non-cancer tissues.

Authors:  Nobuyuki Kakiuchi; Seishi Ogawa
Journal:  Nat Rev Cancer       Date:  2021-02-24       Impact factor: 60.716

7.  IDH mutation and 1p19q codeletion distinguish two radiological patterns of diffuse low-grade gliomas.

Authors:  Amélie Darlix; Jérémy Deverdun; Nicolas Menjot de Champfleur; Florence Castan; Sonia Zouaoui; Valérie Rigau; Michel Fabbro; Yordanka Yordanova; Emmanuelle Le Bars; Luc Bauchet; Catherine Gozé; Hugues Duffau
Journal:  J Neurooncol       Date:  2017-04-22       Impact factor: 4.130

8.  Gene Expression Profiling Stratifies IDH1-Mutant Glioma with Distinct Prognoses.

Authors:  Wen Cheng; Xiufang Ren; Chuanbao Zhang; Jinquan Cai; Sheng Han; Anhua Wu
Journal:  Mol Neurobiol       Date:  2016-09-30       Impact factor: 5.590

9.  Combined Cohesin-RUNX1 Deficiency Synergistically Perturbs Chromatin Looping and Causes Myelodysplastic Syndromes.

Authors:  Yotaro Ochi; Ayana Kon; Toyonori Sakata; Masahiro M Nakagawa; Naotaka Nakazawa; Masanori Kakuta; Keisuke Kataoka; Haruhiko Koseki; Manabu Nakayama; Daisuke Morishita; Tatsuaki Tsuruyama; Ryunosuke Saiki; Akinori Yoda; Rurika Okuda; Tetsuichi Yoshizato; Kenichi Yoshida; Yusuke Shiozawa; Yasuhito Nannya; Shinichi Kotani; Yasunori Kogure; Nobuyuki Kakiuchi; Tomomi Nishimura; Hideki Makishima; Luca Malcovati; Akihiko Yokoyama; Kengo Takeuchi; Eiji Sugihara; Taka-Aki Sato; Masashi Sanada; Akifumi Takaori-Kondo; Mario Cazzola; Mineko Kengaku; Satoru Miyano; Katsuhiko Shirahige; Hiroshi I Suzuki; Seishi Ogawa
Journal:  Cancer Discov       Date:  2020-04-05       Impact factor: 39.397

10.  IDH1 Associated with Neuronal Apoptosis in Adult Rats Brain Following Intracerebral Hemorrhage.

Authors:  Xing Chen; Hongmei Wang; Weibing Yu; Fen Chen; Guiyun Wang; Jiajia Shi; Chunying Zhou
Journal:  Cell Mol Neurobiol       Date:  2016-08-27       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.